- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Diseases
Lilly letting U.S. researchers test failed compounds for new uses
May 3, 2012
Bloomberg NewsMore than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by
U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed
at previously.
MoreLilly wins FDA approval for Alzheimer's imaging agent
April 9, 2012
J.K. WallThe agent, called Amyvid, is not expected to produce high-dollar sales for Lilly, but it could help to identify patients with
Alzheimer’s—and those without it—earlier, perhaps improving treatment and focusing research efforts.
MoreLilly receives Europe's OK for new Byetta use
March 23, 2012
IBJ Staff and Associated Press, Associated PressEuropean regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin
Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
MoreLilly to focus on cancer, diabetes in China, CEO says
March 20, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years,
focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
MoreIndiana measles outbreak illustrates disease risk
February 15, 2012
Associated PressIndiana is battling its second measles outbreak in two years, even though its vaccination rate exceeds the national average.
Health officials say the cases, traced to a Super Bowl event, illustrate just how vulnerable the public is to exposure from
sources at home and abroad.
MoreQ&A
December 27, 2011
J.K. WallDr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.
Ball State: Diabetes rising at alarming rate
December 12, 2011
J.K. WallIn 1993, only 3.8 percent of Hoosier adults had full-blown diabetes, compared with 9.8 percent today.
MoreLilly shares rise on possibility for Alzheimer’s drug
December 7, 2011
Bloomberg NewsEli Lilly and Co. stock rose to a one-month high Tuesday after an analyst said the possible success of the company’s
experimental Alzheimer’s drug could double the share price.
MoreQ&A
December 5, 2011
J.K. WallCarmel resident David Wasilewski has launched WhatNext, a website that uses algorithms to make it easier
for cancer patients to connect with others in similar circumstances. Wasilewski, 39, spent eight years as chief operating
officer of the Spanx line of body shapers and did health care consulting before that. In addition to helping patients, he
thinks WhatNext can become a way for health care organizations share their expertise with patients in need.
MoreLilly, Amylin agree to end diabetes partnership
November 8, 2011
Bloomberg News, Associated PressAmylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation.
Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.
MoreGlucose monitor deal helps Roche catch up
November 7, 2011
J.K. WallRoche Diagnostics will partner with a San Diego firm to incorporate its continuous glucose monitoring sensor with a wireless
handheld device Roche is developing to help diabetics test their blood sugar and track their glucose levels throughout the
day.
MoreLilly hid Zyprexa's diabetes risks, family’s lawyer argues
November 2, 2011
Bloomberg NewsEli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who
died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award
the family $40 million in compensatory damages.
MoreIU med school gets $9M for Alzheimer's center
November 1, 2011
J.K. WallThe grant is the fifth consecutive five-year grant the Alzheimer Disease Center has received from NIH to support research
to understand the causes and potential treatments for Alzheimer’s and other forms of dementia.
MoreLilly fights view that fate hinges on Alzheimer's drug
October 29, 2011
Greg AndrewsAnalysts have eyes on trial data for drug that could be a game-changer for the company.
MoreFDA approves Cialis for enlarged prostate
October 7, 2011
Cialis, Lilly's blockbuster erectile dysfunction drug, now can be taken to treat enlarged prostate. FDA approval means men
who suffer from both disorders can take one medication.
MoreDebate rages over whether Lilly's Byetta lifts cancer risk
September 16, 2011
Bloomberg NewsA German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
MoreIU Cancer Center recruits top researcher
September 15, 2011
Scott OlsonDr. Murray Korc, an internationally known pancreatic cancer researcher, comes to the cancer center as the first Myles Brand
Professor of Cancer Research. The position is funded through a Lilly Endowment grant.
MoreLilly, partner find no Bydureon effect on heart rhythm
June 27, 2011
Bloomberg NewsEli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. said an analysis of a 148-patient trial found no evidence
that their experimental Bydureon diabetes drug causes prolonged heart rhythms.
MoreLilly diabetes pill recommended for EU approval
June 24, 2011
Bloomberg NewsEli Lilly and Co. and Boehringer Ingelheim GmbH’s Trajenta medicine for Type 2 diabetes has been recommended for approval
in Europe, putting the drug on track to enter the region’s market this year.
MoreBrain barrier breached in push to deliver Alzheimer's drug
May 25, 2011
Scientists with Roche Holding AG, the parent company of Indianapolis-based Roche Diagnostics Corp., may have found a way to
overcome a blood barrier that keeps drugs from directly entering the brain, potentially opening new pathways to attack Alzheimer’s
disease.
MoreLilly drug to detect Alzheimer’s criticized by consumer group
May 11, 2011
Bloomberg NewsEli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain,
shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
MoreFDA OKs new diabetes pill from Lilly, Boehringer
May 2, 2011
IBJ Staff and Associated PressThe Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients
who can't control their blood sugar with older medicines.
MoreLilly teams with Medtronic on Parkinson's treatment
April 26, 2011
J.K. WallEli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients'
brains with an experimental drug for Parkinson’s disease.
MoreRoche wins approval of HPV test
April 25, 2011
J.K. WallRoche Diagnostics Corp. won regulatory approval for a new HPV test, giving it a technological edge in the $300 million market
for automated cervical cancer tests.
MoreFDA wants further testing of Lilly pancreas drug
April 16, 2011
Associated PressEli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed
pancreas drug before it resubmits an application to have the drug approved for sale.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
See, I told u Indyman and Dipsicle....this 8 days is overkill. It's barely worth a weekend....great job Tony George! Your dream has been fulfilled....he fans want the I r l back. Thats how good it was.....and that sucked.
I have been in training for a short time now but right off I can see that safety and quality are the number one issues, my experience as of late has been a positive one, the employees along with Jeff the plant manager and the operation supervisor as well as the engineers are a highly motivated group of people, what an asset for the area to have and for company's in need of a quality metal products.
Pimlico
While I understand the severity of their actions as well as everyones eagerness to hold them responsible for thier lost funds, these gentlemen did know how to make money. Dispite thier poor decisions over the ownership of Fair they had made several wise investments which paid them greatly. This proves they do have the potential to rebuild so they can repay. I do not feel they should live the life of luxuary but given an opportunity could they find ways of repaying the debts? They are doing nothing now but being a burden on tax payers. Just a thought!!!!!
You guys have some "interesting" comments to say the least. I hope you will call in and share those opinions starting June 1. I'm looking forward to having you on the air.